Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alemtuzumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    99 result(s) found for: Alemtuzumab. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2018-001489-41 Sponsor Protocol Number: P00003466 Start Date*: 2018-07-02
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease
    Medical condition: Dyskeratosis congenita / telomere disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005074-69 Sponsor Protocol Number: CAM203 Start Date*: 2006-07-05
    Sponsor Name:Genzyme Europe BV
    Full Title: Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH, MabCampath) in Patients with Previously Treated B Cell Chronic Lymphocytic Leukemia
    Medical condition: B-Cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-001770-29 Sponsor Protocol Number: KKS-256 Start Date*: 2019-11-19
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Viral load guided Immunosuppression after Lung Transplantation An open-label, randomized, controlled, parallel-group, multicenter trial (VIGILung)
    Medical condition: Prophylaxis against lung transplant rejection Clinical experience suggests that individual tailoring of immunosuppression for patients after lung transplantation could potentially optimize patient ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002476-15 Sponsor Protocol Number: GIMEMALLC0405 Start Date*: 2005-07-28
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Phase II pilot trial to evaluate the efficacy and safety of a first-line combined therapeutic approach for young (> = 60 years old) CLL patients with advanced and progressive disease stratif...
    Medical condition: CLL patients (diagnosis of CLL according to NCI criteria) with the following characteristics: Advanced stage or progressive disease with at least 2 clinical features of activity. Previously untreat...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005049-36 Sponsor Protocol Number: CAMPATH Start Date*: 2005-02-03
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: CAMPATH-1H MONOCLONAL ANTIBODY AS MANTEINANCE THERAPY AFTER FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINATION REGIMEN AS 2ND LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Medical condition: B-CLL DISEASE
    Disease: Version SOC Term Classification Code Term Level
    Nd 10008958 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006694-24 Sponsor Protocol Number: IV-A05-LL-01-PR.03 Start Date*: 2007-07-16
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia
    Medical condition: relapsed or refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011225-14 Sponsor Protocol Number: Le.P.Re. Study Start Date*: 2009-05-22
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
    Medical condition: Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia, [Hallek M et al, 2008]).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001892-12 Sponsor Protocol Number: 00557 Start Date*: 2007-10-15
    Sponsor Name:University Medical Centre Freiburg
    Full Title: Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation (Everolimus und Mycophenolsäure als GvHD-Prophylaxe in der allogenen Blutstammzelltransplantation)
    Medical condition: Prophylaxis of graft-versus-host disease after allogenous blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019983-35 Sponsor Protocol Number: VPA-CdA Start Date*: 2010-11-24
    Sponsor Name:Cliniques universitaires Saint Luc
    Full Title: Phase I-II study of low dose CdA combined with valproic acid (VPA) in previously treated B-cell chronic lymphocytic leukemia (CLL) patients.
    Medical condition: •B-CLL, as defined by the NCIWG criteria •Patients must have intermediate or high-risk categories of the modified 3-stage Rai and Binet stagings
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000121-30 Sponsor Protocol Number: FCC Start Date*: 2004-12-27
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: An Open Label Pilot study with oral fludarabine, oral cyclophosphamide and CAMPATH 1H (FCC) for patients with refractory or Relapsed B cells Chronic Lynphocytic Leukaemia
    Medical condition: B-cells CLL Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004956-60 Sponsor Protocol Number: UCL/08/0121 Start Date*: 2009-08-14
    Sponsor Name:University College London
    Full Title: Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma
    Medical condition: Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008553-27 Sponsor Protocol Number: CTSU3C1 Start Date*: 2009-12-02
    Sponsor Name:University of Oxford
    Full Title: Open-label, randomised multicentre study of CAMPATH-1H versus basiliximab induction treatment and sirolimus versus tacrolimus maintenance treatment for the preservation of renal function in patient...
    Medical condition: Renal transplantation.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004626-28 Sponsor Protocol Number: T214/2013 Start Date*: 2013-12-20
    Sponsor Name:Turku University Hospital
    Full Title: Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-024467-40 Sponsor Protocol Number: GETH-CLL4 Start Date*: 2011-10-11
    Sponsor Name:GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH)
    Full Title: OFATUMUMAB COMO PARTE DEL RÉGIMEN DE ACONDICIONAMIENTO DE INTENSIDAD REDUCIDA PARA PACIENTES CON LEUCEMIA lINFÁTICA CRÓNICA DE ALTO RIESGO QUE RECIBEN UN TRASPLANTE ALOGÉNICO DE PROGENITORES HEMATO...
    Medical condition: PACIENTES CON LEUCEMIA LINFATICA CRONICA DE ALTO RIESGO CONINDICACION DE TRASPLANTE ALOGÉNICO DE INTENSIDAD REDUCIDA Y DISPONIBILIDAD DE DONANTE, YA SEA FAMILIAR O NO EMPARENTADO
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000301-71 Sponsor Protocol Number: TJB1117P1 Start Date*: 2013-01-25
    Sponsor Name:CHU-ULg
    Full Title: Donor Regulatory T cells (Treg) infusion (DTI) in patients with steroid-refractory chronic graft-versus-host disease (GVHD).
    Medical condition: Steroid-refractory chronic graft-versus-host-disease.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001718-41 Sponsor Protocol Number: 0517-31 Start Date*: 2012-09-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of...
    Medical condition: chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed) CZ (Completed) SE (Completed) HU (Completed) IT (Completed) PT (Completed) LV (Completed) PL (Completed) BG (Completed) GR (Completed) NO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001656-35 Sponsor Protocol Number: 109MS408 Start Date*: 2014-04-07
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multipl...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) BE (Completed) PT (Completed) IT (Completed) CZ (Completed) SK (Completed) ES (Completed) SI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023297-39 Sponsor Protocol Number: NETU-10-29 Start Date*: 2011-05-27
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A phase III, multicenter, randomized, double-blind, unbalanced (3:1) active control study to assess the safety and describe the efficacy of netupitant and palonosetron for the prevention of chemoth...
    Medical condition: Nausea and vomiting in cancer patients associated with chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001699-20 Sponsor Protocol Number: 042011 Start Date*: 2012-05-18
    Sponsor Name:St. Anna Kinderkrebsforschung, GmbH
    Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS
    Medical condition: Langerhans cell histiocytosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006152-34 Sponsor Protocol Number: EFC6663 Start Date*: 2007-11-28
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Multicenter, Open-Label, Single Arm Study of Weekly Alvocidib in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising from CLL
    Medical condition: B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) arising from CLL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) NL (Completed) FR (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 09:59:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA